If you’re interested in learning more about Sarcoma, see some of the latest news regarding Sarcoma treatment and clinical drug trials below. Please contact us if you have any questions or would like more information.
News
- CytRx’s Aldoxorubicin
- Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology
- Dr. Chawla’s featured article in Lancet Oncology journal from July 2013 on ground-breaking work in Giant Cell Tumors
- CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma
- Sarcoma Oncology Center Leverages BostonGene’s AI-driven Molecular and Immune Profiling Platform to Identify Novel Treatment Options for Patients with Advanced Cancers
Research
Below you will find links to information regarding clinical trial results and links to other sources you may find useful when researching sarcomas.
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy.
- Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
- Sarcoma Information from the American Cancer Society
- What You Need to Know About Sarcoma from the Sarcoma Alliance
- ANTICANCER RESEARCH – International Journal of Cancer Research and Treatment, From Mendel to Gene Therapy
- SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
- Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas
- Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor
- Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies
Contact the Sarcoma Oncology Center Today for More Information
We are here to help you through this journey. If you would like more information on Sarcoma News & Research, please contact our specialists at 310-552-9999 today.
Next, read our blog.